Enrollment in Ph 1 dose escalation ACESOT-1051 trial accelerating
“Expanding enrollment and adding combination regimens in HPV positive head and neck cancer and colorectal cancer will broaden the clinical dataset as we advance development of ACESOT-1051,” said Gene Kennedy, M.D., Chief Medical Advisor of Aprea. “We look forward to sharing the next set of data from the trial at a medical meeting in the fourth quarter of this year,”.
Share:
More News
“This collaboration with Daiichi Sankyo represents an exciting milestone for our hematology franchise. Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence including TYVYT® (sintilimab injection), HALPRYZA® (rituximab injection), olverembatinib, FUCASO® (Equecabtagene Autoleucel Injection), Jaypirca® (pirtobrutinib), and the addition of
“The initiation of our global Phase 3 program marks an important milestone for BL-M14D1 and reflects our commitment to bringing innovative treatment options to patients with small cell lung cancer,” said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. “Despite recent advances, outcomes for patients with extensive-stage small cell lung
Dr. Michael Ge, CEO of Kelun-Biotech, said, “Following the approval of sac-TMT for second-line or later treatment of TNBC based on results from the Phase III OptiTROP-Breast01 study, we are delighted to see another important milestone in the same disease area. For patients with PD-L1-negative advanced TNBC, the efficacy of
Dr. Shawn M. Leland, PharmD, RPh, Board Chairman of Evexta Bio stated: “We are very pleased and excited to partner with Roche on Evexta Bio’s first clinical collaboration with rupitasertib. ER+, HER2-, ESR1-mutated breast cancer remains a significant unmet medical need. We are looking forward to being able to provide